Mereo BioPharma Group plc — FY2023 Form 10-K Summary
Business context and reporting period
Mereo is a U.K.-based, clinical-stage biopharmaceutical company focused on rare-disease therapeutics. The filing covers the year ended December 31, 2023; it is an annual report rather than a standalone fourth-quarter filing. Mereo has no approved products and has never generated product-sale revenue. Its principal programs are setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and etigilimab for advanced solid tumors. Navicixizumab is licensed to Feng Biosciences, and leflutrozole was licensed to ReproNovo in December 2023.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $10.0 million | $0 | +$10.0 million |
| Loss from operations | $28.4 million loss | $54.4 million loss | Improved by $26.0 million |
| Research and development expense | $17.4 million | $29.5 million | Down 41% |
| General and administrative expense | $18.4 million | $26.1 million | Down 29% |
| Net loss | $29.5 million | $42.2 million | Improved by $12.8 million |
| Net loss per share | $0.04 | $0.07 | Improved |
| Net cash used in operating activities | $21.1 million | $48.8 million | Use declined by $27.7 million |
| Cash and cash equivalents | $57.4 million | $68.2 million | Down $10.8 million |
FY2023 revenue consisted of a $9.0 million setrusumab clinical milestone from Ultragenyx and a $1.0 million upfront payment from ReproNovo for leflutrozole. Revenue was non-recurring and did not represent product sales. Gross margin and operating margin are not economically meaningful because revenue was primarily milestone-based and the company remains pre-commercial.
Interest income increased to $2.1 million from $0.8 million, while interest expense declined to $2.9 million from $4.2 million. The company reported a $2.3 million foreign-exchange loss versus a $2.7 million gain in 2022. Total assets were $66.5 million and shareholders’ equity was $50.5 million at year-end.
At December 31, 2023, convertible loan notes totaled $4.4 million on a non-current basis. The Private Placement Loan Notes were converted or fully settled during 2023. The remaining Novartis Loan Note has a maturity date of February 10, 2025 and a 9% interest rate. Outstanding warrants totaled approximately 2.5 million ordinary shares, or 0.4% of issued ordinary share capital.
Material changes versus the prior comparable period
- Revenue increased from zero to $10.0 million due to the Ultragenyx milestone and ReproNovo upfront payment.
- R&D expense declined primarily because etigilimab development activity wound down; setrusumab spending increased as the program advanced.
- G&A expense declined because of lower staffing, professional-fee and corporate costs, reimbursement of certain depositary expenses, and a directors’ and officers’ insurance recovery.
- Operating cash burn improved substantially, but cash declined to $57.4 million after financing and investing activity.
- Mereo raised approximately $12.0 million gross through a July 2023 at-the-market offering and received approximately $11.1 million net proceeds.
- Shares outstanding increased to approximately 701.2 million at December 31, 2023 from 624.9 million at December 31, 2022, reflecting equity issuance, debt conversions and share-based awards.
- Private-placement warrants covering approximately 161.0 million ordinary shares expired in June 2023, materially reducing warrant overhang.
- The company changed from foreign-private-issuer reporting to domestic U.S. reporting beginning January 1, 2024, increasing compliance and reporting requirements.
- A material weakness identified during the first half of 2023 related to the presentation of a significant non-routine transaction was reported as remediated at December 31, 2023. Management concluded that disclosure controls and internal control over financial reporting were effective at year-end.
Clinical, strategic and operational outlook
- Setrusumab: The Phase 2 portion of the Orbit study reported significant biomarker and bone-mineral-density improvements. The company reported a 67% reduction in annualized fracture rate after at least six months of treatment, but these results remain from a small Phase 2 population. Phase 3 Orbit and Cosmic studies were expected to complete enrollment around the end of the first quarter of 2024.
- Alvelestat: Phase 2 ASTRAEUS and investigator-led ATALANTa data supported further development in AATD-LD. Mereo is designing a global Phase 3 study of approximately 220 patients at a 240 mg dose, subject to financing and execution. The company continues to evaluate non-dilutive funding and potential partnerships.
- Etigilimab: The Phase 1b portion of the ACTIVATE study was completed with 76 patients. Mereo stated that it does not plan to directly fund additional clinical studies, while an investigator-led EON study continues with Cancer Focus Fund financing.
- Leflutrozole: ReproNovo assumed future development and commercialization responsibilities. Mereo received $1.0 million upfront and may receive up to $64.3 million in milestones plus tiered mid-single-digit royalties.
- Setrusumab partnership economics: Ultragenyx leads global development and holds commercial rights outside Europe, while Mereo retains European and U.K. rights. Mereo received a $9.0 million 2023 milestone and is eligible for additional milestones and royalties.
- Management expects existing cash to fund current operating expenses and capital requirements into 2026, but states that additional capital will be required to complete development plans and potentially commercialize products.
Risks, contingencies and unusual items
- Mereo remains loss-making, has an accumulated deficit of $419.6 million, and has no approved products or product-sale revenue.
- Future funding is required; equity or debt financing could dilute shareholders or impose restrictive terms, while partnerships could require relinquishing economic or development rights.
- Clinical and regulatory success is uncertain, particularly for setrusumab and alvelestat. Early or interim clinical results may not predict pivotal-trial outcomes.
- The company relies on Ultragenyx, ReproNovo, Feng Biosciences, CROs and third-party manufacturers. Delays, underperformance, insolvency or termination by these parties could materially affect development and revenue prospects.
- Manufacturing commitments to CMOs were $4.2 million at December 31, 2023. Setrusumab manufacturing has exhibited a potential opalescence issue, although the company states that it has not affected potency or effectiveness in completed manufacturing runs.
- Potential milestone, royalty and other obligations remain under agreements with Novartis and AstraZeneca. The timing and amount of these obligations are uncertain.
- The CVR arrangement expires April 23, 2024 and had a recorded fair value of zero at year-end, although gross potential payments were approximately $80 million if specified milestones were achieved.
- The company disclosed known risks from foreign-exchange volatility, Brexit-related regulatory and supply-chain complexity, cybersecurity incidents, healthcare-price controls, reimbursement uncertainty and intellectual-property disputes.
- There were no material legal proceedings at December 31, 2023. The filing text does not provide a clear going-concern qualification; management states that it expects cash to fund operations for at least 12 months from filing and into 2026 under its current plan.
Most important facts for investors to verify
- Whether Orbit and Cosmic Phase 3 studies met enrollment and subsequent clinical milestones after the filing date.
- The design, financing, timing and regulatory alignment of the planned alvelestat Phase 3 trial.
- Cash runway, quarterly operating burn and the timing and terms of required future financing.
- Remaining obligations and potential dilution from the Novartis note, warrants, equity awards and other contractual commitments.
- Whether milestone revenue from partners is recurring or achievable in future periods; FY2023 revenue was entirely milestone and upfront-license based.
- ReproNovo’s and Feng Biosciences’ ability to fund and advance their licensed programs.
- Potential Novartis and AstraZeneca royalties, milestone payments and licensing consequences if programs advance or are partnered.
- Regulatory, reimbursement, manufacturing and intellectual-property developments affecting setrusumab and alvelestat.